Eli Lilly and Company (NYSE:LLY) Reaches New 1-Year High - Time to Buy?

Key Points

• Eli Lilly shares reached a new 52-week high of $1,304.31, supported by strong relative performance and continued investor interest as technology stocks weakened. Analysts largely remain positive, with a “Moderate Buy” consensus and an average price target of $1,313.43.
• Growth is being driven primarily by Lilly’s GLP-1 portfolio, including Mounjaro, Zepbound and the oral treatment Foundayo. The company also reported quarterly revenue growth of 47.7% year over year and earnings that exceeded analyst expectations.
• Risks include Lilly’s elevated valuation, potential weight-loss drug price competition and legal exposure related to allegations of insulin-price inflation. Recent insider selling and the stock’s dependence on GLP-1 products may also limit enthusiasm despite promising pipeline and partnership developments.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $1,304.31 and last traded at $1,300.4580, with a volume of 817,801 shares changing hands. The stock had previously closed at $1,240.34.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: GLP-1 growth remains the primary catalyst. Analysts expect Mounjaro, Zepbound and the oral GLP-1 treatment Foundayo to support upcoming third-quarter results. Bank of America expects Foundayo to continue gaining market share over the next year, while Lilly’s growth and improving margins could help justify its premium valuation. How will Eli Lilly's GLP-1 portfolio sales aid upcoming Q3 results?
• Positive Sentiment: Omvoh produced encouraging pediatric ulcerative-colitis data. In the Phase 3 SHINE-2 study, 81% of patients achieved a clinical response after induction, and 50% of responders reached clinical remission at one year. Lilly plans to submit the data to regulators for a potential label expansion, adding to the company’s longer-term revenue diversification. Lilly's Omvoh pediatric ulcerative-colitis study
• Positive Sentiment: Pipeline and partnership news support future growth. Lilly will present oncology data at the 2026 ESMO Congress and agreed to pay Metis TechBio up to $1.1 billion for AI-enabled drug-delivery technology, potentially strengthening future development capabilities. Metis TechBio deal with Eli Lilly
• Neutral Sentiment: Relative strength is attracting investors. Lilly has outperformed broader indexes over recent months and is trading close to its high, benefiting from defensive demand as technology and AI stocks weaken. RBC also issued a Buy rating, although the stock’s elevated earnings multiple leaves less room for disappointment. RBC Buy rating
• Negative Sentiment: Competitive and legal risks are limiting enthusiasm. A potential weight-loss drug price war with Novo Nordisk, concentrated dependence on GLP-1 products and Lilly’s premium valuation could pressure the shares. Separately, a Pennsylvania lawsuit alleges insulin-price inflation exceeding 1,000%; the claims remain unproven but add headline and regulatory risk. Eli Lilly insulin pricing lawsuit

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on LLY shares. UBS Group set a $1,376.00 target price on shares of Eli Lilly and Company in a research note on Friday, August 7th. Wall Street Zen lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Saturday. TD Cowen reissued a "buy" rating and set a $1,250.00 target price on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. Sanford C. Bernstein increased their target price on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an "outperform" rating in a report on Tuesday, July 14th. Finally, Citigroup raised their target price on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a "buy" rating in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average target price of $1,313.43.

Eli Lilly and Company Price Performance

The stock's 50-day moving average price is $1,180.34 and its 200 day moving average price is $1,111.84. The firm has a market capitalization of $1.22 trillion, a price-to-earnings ratio of 43.59, a PEG ratio of 1.67 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company's revenue for the quarter was up 47.7% on a year-over-year basis. During the same period last year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts expect that Eli Lilly and Company will post 33.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. The trade was a 29.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the business's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $15,958,170 in the last ninety days. 0.14% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Eli Lilly and Company

Institutional investors have recently added to or reduced their stakes in the stock. Boyd Wealth Management LLC bought a new position in Eli Lilly and Company during the 3rd quarter worth approximately $520,000. Focused Alpha LLC boosted its stake in Eli Lilly and Company by 142.1% in the third quarter. Focused Alpha LLC now owns 983 shares of the company's stock valued at $1,137,000 after acquiring an additional 577 shares during the period. tru Independence LLC boosted its stake in Eli Lilly and Company by 7.3% in the third quarter. tru Independence LLC now owns 427 shares of the company's stock valued at $494,000 after acquiring an additional 29 shares during the period. Freedom Day Solutions LLC increased its position in Eli Lilly and Company by 3.2% in the third quarter. Freedom Day Solutions LLC now owns 4,797 shares of the company's stock worth $5,551,000 after buying an additional 148 shares during the period. Finally, Mayfair Advisory Group LLC increased its holdings in shares of Eli Lilly and Company by 4.7% in the 3rd quarter. Mayfair Advisory Group LLC now owns 1,414 shares of the company's stock worth $1,636,000 after acquiring an additional 63 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.